Experienced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

Dr. Chiara Battelli

Hematology | Oncology
Maine Center For Cancer Medicine And Blood Disorders PA
155 Borthwick Ave, Suite C, 
Portsmouth, NH 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Maine Center For Cancer Medicine And Blood Disorders PA
155 Borthwick Ave, Suite C, 
Portsmouth, NH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Chiara Battelli is a Hematologist and an Oncologist in Portsmouth, New Hampshire. Dr. Battelli is rated as an Experienced provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and HER-2 Positive Breast Cancer.

Her clinical research consists of co-authoring 8 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in ME
Hospital Affiliations
Mainehealth Maine Medical Center
The Memorial Hospital
Northern Light Mercy Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Options
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
MVP Health
  • EPO
  • PPO
NH Healthy Families
  • EPO
  • MANAGED MEDICAID PLAN
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

MAINE CENTER FOR CANCER MEDICINE AND BLOOD DISORDERS PA
155 Borthwick Ave, Suite C, Portsmouth, NH 03801

Additional Areas of Focus

Dr. Battelli has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
Enrollment Status: Recruiting
Publish Date: January 13, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Trastuzumab, Pertuzumab, Letrozole, Anastrozole, Exemestane, Fulvestrant
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting
Enrollment Status: Terminated
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Sacituzumab Govitecan-hziy
Study Phase: Phase 2
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
View 10 Less Clinical Trials

8 Total Publications

TRADE: A phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast cancer.
TRADE: A phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 21, 2025
Similar Doctors
Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Jennifer A. Chan
Oncology
Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Jennifer A. Chan
Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (52.6 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jennifer Chan is an Oncologist in Boston, Massachusetts. Dr. Chan is rated as a Distinguished provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). Her top areas of expertise are Neuroendocrine Tumor, Metastatic Insulinoma, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), and Pancreatic Islet Cell Tumor. Dr. Chan is currently accepting new patients.

Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Lawrence S. Blaszkowsky
Oncology | Hematology
Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Lawrence S. Blaszkowsky
Oncology | Hematology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 (50.3 miles away)
617-726-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lawrence Blaszkowsky is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Blaszkowsky is rated as an Elite provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Tissue Biopsy.

Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Matthew H. Kulke
Oncology
Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Matthew H. Kulke
Oncology

Evans Medical Foundation Inc

88 E Newton St, 
Boston, MA 
 (52.1 miles away)
617-414-5405
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Matthew Kulke is an Oncologist in Boston, Massachusetts. Dr. Kulke is rated as an Elite provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Carcinoid Syndrome, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), and Liver Embolization. Dr. Kulke is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Battelli's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 42 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile